

IN THE CLAIMS:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A vaccine comprising a C-terminal 42 kD fragment of merozoite surface protein-1 (MSP-1<sub>42</sub>) from *P. falciparum* 3D7, SEQ ID NO:2, that is recombinantly expressed in *E. coli* as a soluble protein that retains its native structure and an adjuvant ~~selected from the group consisting of A, B, C, D, and E.~~

2. (Cancelled)

3. (Currently amended) A method for inducing an immune response to malaria in a subject comprising administering to said subject a composition comprising an immunologically effective amount of C-terminal 42 kD fragment of merozoite surface protein-1 (MSP-1<sub>42</sub>) from *P. falciparum* 3D7, SEQ ID NO:2, that is recombinantly expressed in *E. coli* as a soluble protein that retains its native structure in an acceptable diluent and an adjuvant ~~chosen from the group consisting of A, B, C, D, and E.~~

4. (Cancelled)

5. (Currently amended ) A method for inducing a protective immune response to malaria in a mammal, comprising

administering a composition comprising a MSP-1<sub>42</sub> from *P. falciparum* 3D7, SEQ ID NO:2, that is recombinantly expressed in *E. coli* as a soluble protein that retains its native structure in an amount effective to induce an immune response in said mammal and an adjuvant ~~selected from the group consisting of A, B, C, D, and E.~~

6. (Cancelled)

7. (Original) The method of claim 5, wherein the composition is administered to the individual in an amount of 50 ug per dose.
8. (Original) The method of claim 5, wherein the composition is administered parenterally.
9. (Original) The method of claim 5, wherein the composition is administered intranasally.
10. (Original) The method of claim 5, wherein said administration is a multiple administration.
11. (Original) The method according to claim 10 wherein said multiple administration is at 0 and 6 months.
12. (New) The vaccine of claim 1, wherein the adjuvant is a formulation of 0.25 mg cholesterol, 1 mg dioleoyl phosphatidylcholine, 50  $\mu$ g 3D-MPL, and 50  $\mu$ g QS21, consisting of small liposomes, wherein the QS21 and the 3D-MPL are in the membranes of the liposomes.
13. (New) The vaccine of claim 1, wherein the adjuvant is a formulation of 10.68 mg squalene, 11.86 mg tocopherol, 4.85 mg Tween 80, 50  $\mu$ g 3D-MPL, and 50  $\mu$ g QS21 and consisting of an oil-in-water emulsion comprising the squalene and alpha-tocopherol, the emulsion being in admixture with the QS21 and 3-DPML.
14. (New) The vaccine of claim 1, wherein the adjuvant is a formulation of 0.25 mg cholesterol, 1 mg dioleoyl phosphatidylcholine, 50  $\mu$ g 3D-MPL, 50  $\mu$ g QS21 and 0.5 mg  $\text{AlOH}_3$ , said formulation consisting of small liposomes wherein the QS21 and 3D-MPL are in the membranes of the liposomes and wherein the liposomes and the antigen are absorbed onto a metallic salt particle carrier.

15. (New) The vaccine of claim 1, wherein the adjuvant is a formulation of 0.5 mg  $\text{AlOH}_3$ , 500  $\mu\text{g}$  of unmethylated immunostimulatory oligonucleotide CpG wherein antigen and immunostimulant (CpG) are absorbed onto a metallic salt particle carrier.

16. (New) The vaccine of claim 1, wherein the adjuvant is a formulation of 0.25 mg cholesterol, 1 mg dioleoyl phosphatidylcholine, 50  $\mu\text{g}$  QS21, and 0.5 mg  $\text{AlOH}_3$ , consisting of small unilamellar vesicles wherein the QS21 is in the membranes of the vesicles and wherein the vesicles and the antigen are absorbed onto a metallic salt particle carrier.